Cargando…

DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity

Deficiencies in DNA repair due to mutations in the exonuclease domain of DNA polymerase ɛ have recently been described in a subset of cancers characterized by an ultramutated and microsatellite stable (MSS) phenotype. This alteration in DNA repair is distinct from the better‐known mismatch repair de...

Descripción completa

Detalles Bibliográficos
Autores principales: Castellucci, Enrico, He, Tianfang, Goldstein, D. Yitzchak, Halmos, Balazs, Chuy, Jennifer
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AlphaMed Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423519/
https://www.ncbi.nlm.nih.gov/pubmed/28465371
http://dx.doi.org/10.1634/theoncologist.2017-0034
_version_ 1783234960820273152
author Castellucci, Enrico
He, Tianfang
Goldstein, D. Yitzchak
Halmos, Balazs
Chuy, Jennifer
author_facet Castellucci, Enrico
He, Tianfang
Goldstein, D. Yitzchak
Halmos, Balazs
Chuy, Jennifer
author_sort Castellucci, Enrico
collection PubMed
description Deficiencies in DNA repair due to mutations in the exonuclease domain of DNA polymerase ɛ have recently been described in a subset of cancers characterized by an ultramutated and microsatellite stable (MSS) phenotype. This alteration in DNA repair is distinct from the better‐known mismatch repair deficiencies which lead to microsatellite instability (MSI) and an increased tumor mutation burden. Instead, mutations in POLE lead to impaired proofreading intrinsic to Pol ɛ during DNA replication resulting in a dramatically increased mutation rate. Somatic mutations of Pol ɛ have been found most frequently in endometrial and colorectal cancers (CRC) and can lead to a unique familial syndrome in the case of germline mutations. While other key genomic abnormalities, such as MSI, have known prognostic and treatment implications, in this case it is less clear. As molecular genotyping of tumors becomes routine in the care of cancer patients, less common, but potentially actionable findings such as these POLE mutations could be overlooked unless appropriate algorithms are in place. We present two cases of metastatic CRC with a POLE mutation, both of which are ultramutated and MSS. The basic biochemical mechanisms leading to a unique phenotype in POLE deficiency as well as challenges faced with interpreting the genomic profiling of tumors in this important subset of patients and the potential clinical implications will be discussed here. The Oncologist 2017;22:497–502 KEY POINTS. Clinicians should recognize that tumors with high tumor mutation burden and that are microsatellite stable may harbor a POLE mutation, which is associated with an ultramutated phenotype. Work‐up for POLE deficiency should indeed become part of the routine molecular testing paradigm for patients with colorectal cancer. This subset of patients may benefit from clinical trials where the higher number of mutation‐associated neoantigens and defect in DNA repair may be exploited therapeutically.
format Online
Article
Text
id pubmed-5423519
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher AlphaMed Press
record_format MEDLINE/PubMed
spelling pubmed-54235192018-05-01 DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity Castellucci, Enrico He, Tianfang Goldstein, D. Yitzchak Halmos, Balazs Chuy, Jennifer Oncologist Precision Medicine Clinic Deficiencies in DNA repair due to mutations in the exonuclease domain of DNA polymerase ɛ have recently been described in a subset of cancers characterized by an ultramutated and microsatellite stable (MSS) phenotype. This alteration in DNA repair is distinct from the better‐known mismatch repair deficiencies which lead to microsatellite instability (MSI) and an increased tumor mutation burden. Instead, mutations in POLE lead to impaired proofreading intrinsic to Pol ɛ during DNA replication resulting in a dramatically increased mutation rate. Somatic mutations of Pol ɛ have been found most frequently in endometrial and colorectal cancers (CRC) and can lead to a unique familial syndrome in the case of germline mutations. While other key genomic abnormalities, such as MSI, have known prognostic and treatment implications, in this case it is less clear. As molecular genotyping of tumors becomes routine in the care of cancer patients, less common, but potentially actionable findings such as these POLE mutations could be overlooked unless appropriate algorithms are in place. We present two cases of metastatic CRC with a POLE mutation, both of which are ultramutated and MSS. The basic biochemical mechanisms leading to a unique phenotype in POLE deficiency as well as challenges faced with interpreting the genomic profiling of tumors in this important subset of patients and the potential clinical implications will be discussed here. The Oncologist 2017;22:497–502 KEY POINTS. Clinicians should recognize that tumors with high tumor mutation burden and that are microsatellite stable may harbor a POLE mutation, which is associated with an ultramutated phenotype. Work‐up for POLE deficiency should indeed become part of the routine molecular testing paradigm for patients with colorectal cancer. This subset of patients may benefit from clinical trials where the higher number of mutation‐associated neoantigens and defect in DNA repair may be exploited therapeutically. AlphaMed Press 2017-05-02 2017-05 /pmc/articles/PMC5423519/ /pubmed/28465371 http://dx.doi.org/10.1634/theoncologist.2017-0034 Text en © AlphaMed Press 2017
spellingShingle Precision Medicine Clinic
Castellucci, Enrico
He, Tianfang
Goldstein, D. Yitzchak
Halmos, Balazs
Chuy, Jennifer
DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity
title DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity
title_full DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity
title_fullStr DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity
title_full_unstemmed DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity
title_short DNA Polymerase ɛ Deficiency Leading to an Ultramutator Phenotype: A Novel Clinically Relevant Entity
title_sort dna polymerase ɛ deficiency leading to an ultramutator phenotype: a novel clinically relevant entity
topic Precision Medicine Clinic
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5423519/
https://www.ncbi.nlm.nih.gov/pubmed/28465371
http://dx.doi.org/10.1634/theoncologist.2017-0034
work_keys_str_mv AT castelluccienrico dnapolymeraseɛdeficiencyleadingtoanultramutatorphenotypeanovelclinicallyrelevantentity
AT hetianfang dnapolymeraseɛdeficiencyleadingtoanultramutatorphenotypeanovelclinicallyrelevantentity
AT goldsteindyitzchak dnapolymeraseɛdeficiencyleadingtoanultramutatorphenotypeanovelclinicallyrelevantentity
AT halmosbalazs dnapolymeraseɛdeficiencyleadingtoanultramutatorphenotypeanovelclinicallyrelevantentity
AT chuyjennifer dnapolymeraseɛdeficiencyleadingtoanultramutatorphenotypeanovelclinicallyrelevantentity